14:03:30 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-20 Bokslutskommuniké 2024
2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning VIVE 0.00 SEK
2024-05-23 Kvartalsrapport 2024-Q1
2024-05-23 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-26 Ordinarie utdelning VIVE 0.00 SEK
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-25 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-27 Ordinarie utdelning VIVE 0.00 SEK
2022-05-25 Årsstämma 2022
2022-05-25 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-28 Ordinarie utdelning VIVE 0.00 SEK
2021-05-25 Kvartalsrapport 2021-Q1
2020-09-10 Ordinarie utdelning VIVE 0.00 SEK
2020-09-09 Årsstämma 2021
2020-06-18 Bokslutskommuniké 2020
2020-05-14 Extra Bolagsstämma 2020
2020-03-27 Kvartalsrapport 2020-Q3
2019-12-30 Kvartalsrapport 2020-Q2
2019-11-06 Extra Bolagsstämma 2019
2019-09-27 Ordinarie utdelning VIVE 0.00 SEK
2019-09-26 Årsstämma 2020
2019-09-26 Kvartalsrapport 2020-Q1
2019-07-12 Bokslutskommuniké 2019
2019-03-01 Kvartalsrapport 2019-Q3
2018-11-30 Kvartalsrapport 2019-Q2
2018-09-25 Årsstämma 2019
2018-09-05 Ordinarie utdelning VIVE 0.00 SEK
2018-08-31 Kvartalsrapport 2019-Q1
2018-06-08 Bokslutskommuniké 2018
2018-03-02 Kvartalsrapport 2018-Q3
2017-12-01 Kvartalsrapport 2018-Q2
2017-09-26 Ordinarie utdelning VIVE 0.00 SEK
2017-09-25 Årsstämma 2018
2017-09-01 Kvartalsrapport 2018-Q1
2017-06-08 Bokslutskommuniké 2017
2017-03-03 Kvartalsrapport 2017-Q3
2016-12-02 Kvartalsrapport 2017-Q2
2016-11-21 Extra Bolagsstämma 2016
2016-09-27 Ordinarie utdelning VIVE 0.00 SEK
2016-09-26 Årsstämma 2017
2016-09-02 Kvartalsrapport 2017-Q1
2016-06-03 Bokslutskommuniké 2016
2016-03-03 Kvartalsrapport 2016-Q3
2015-12-03 Kvartalsrapport 2016-Q2
2015-09-29 Ordinarie utdelning VIVE 0.00 SEK
2015-09-28 Årsstämma 2016
2015-09-03 Kvartalsrapport 2016-Q1
2015-06-04 Bokslutskommuniké 2015
2015-03-05 Kvartalsrapport 2015-Q3
2014-12-04 Kvartalsrapport 2015-Q2
2014-09-30 Ordinarie utdelning VIVE 0.00 SEK
2014-09-29 Årsstämma 2015
2014-09-05 Kvartalsrapport 2015-Q1
2014-06-05 Bokslutskommuniké 2014
2014-03-06 Kvartalsrapport 2014-Q3
2013-12-05 Kvartalsrapport 2014-Q2
2013-10-01 Ordinarie utdelning VIVE 0.00 SEK
2013-09-06 Kvartalsrapport 2014-Q1
2013-06-07 Bokslutskommuniké 2013
2013-03-13 15-7 2013
2013-03-01 Kvartalsrapport 2012-Q3
2012-12-06 Kvartalsrapport 2012-Q2
2012-09-25 Ordinarie utdelning VIVE 0.00 SEK
2012-09-24 Årsstämma 2012
2012-09-06 Kvartalsrapport 2012-Q1
2012-06-14 Bokslutskommuniké 2011
2012-03-08 Kvartalsrapport 2011-Q3
2011-12-08 Kvartalsrapport 2011-Q2
2011-10-03 Ordinarie utdelning VIVE 0.00 SEK
2011-09-30 Årsstämma 2011
2011-09-08 Kvartalsrapport 2011-Q1
2011-06-10 Bokslutskommuniké 2010
2010-12-09 Kvartalsrapport 2010-Q2
2010-09-24 Årsstämma 2010
2010-09-09 Kvartalsrapport 2010-Q1
2009-12-10 Kvartalsrapport 2009-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Vivesto är ett forskningsbolag. Bolaget är specialiserat inom forskning och utveckling av läkemedel för svåra sjukdomar inom onkologi. Tekniken baseras på bolagets tekniska plattform där forskning sker utifrån nanoteknik. Idag innehas verksamhet främst inom Norden och Nordamerika. Bolaget grundades under 1999 och har idag sitt huvudkontor i Uppsala.
2022-03-28 12:45:00

Solna, Sweden, 28 March 2022 – Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, announces that as of today, 28 March, its new name, Vivesto AB, has been registered with the Swedish Companies Registration Office. As a result of the name change, the company will also change the name and short name (ticker) of its share and paid subscribed shares (“BTA”).

The new name, Vivesto AB, which was approved at the Extraordinary General Meeting on 21 February 2022, reflects the company’s commitment to improve survival and quality of life for patients with cancer through investment in R&D and innovation and marks the end of a turn-around period for the company culminating in the recent successful financing which now provides ample funding for the future operations including key clinical trials.

François Martelet, CEO, said: “We are excited to start a new chapter for Vivesto with the recent completion of the rights issue, which created solid foundations that will enable us to continue to achieve our strategic goals by funding existing operations and clinical trials of our lead products in the next 18-24 months. We are now fully focused on making our ‘string of pearls’ strategy a reality by adding promising and innovative oncology programs to our pipeline through in-licensing and M&A. Our new identity encapsulates our mission to support life through a diversified portfolio of cancer therapies, and we have built a powerful platform for future growth.”

Change of name and short name (ticker)
The name of the share on Nasdaq Stockholm will change from Oasmia Pharmaceutical AB to Vivesto AB and its ticker from OASM to VIVE. The name of the BTA will change from Oasmia Pharmaceutical AB BTA to Vivesto AB BTA and its short name OASM BTA to VIVE BTA.

The ISIN code of the company’s share and BTA will remain unchanged. The last day for trading with the current tickers is today, 28 March 2022. The first day for trading with the new tickers will be on 29 March 2022.

This is an administrative matter. Shareholders therefore do not need to take any action.

The Company worked with the Brand Institute to develop its new identity. Vivesto was ranked highly for brand recognition and relevance by patients, medical professionals and investors surveyed in Europe, the US and Sweden.

For More Information: 

Vivesto AB
Francois Martelet, Chief Executive Officer 
Phone: +46 18-50 54 40 
E-mail: IR@vivesto.com

Consilium Strategic Communications (For Vivesto)
Jonathan Birt, Ashley Tapp
Phone: +44 (0)20 3709 5700 
E-mail: vivesto@consilium-comms.com

About Vivesto
Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Vivesto has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Vivesto’s shares are traded on Nasdaq Stockholm (VIVE). To find out more about Vivesto please visit www.vivesto.com.